Dragonfly Therapeutics Announces First Patient Dosed in Clinical Trial Evaluating Solid Tumor Targeting TriNKET Conducted by Merck

WALTHAM, Mass., Nov. 1, 2022. Dragonfly Therapeutics, Inc. ( " Dragonfly " ), today announced that the first patient has been dosed in a clinical trial being conducted by Merck, known as MSD outside the United States and Canada, to evaluate a solid...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials